46 /100
MEDIUM RISK
Score updated Jul 14, 2026

PHAT — Phathom Pharmaceuticals, Inc. Dilution Risk Tracker

Track PHAT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track PHAT — Get alerts when the score changes →

As of July 14, 2026, Phathom Pharmaceuticals, Inc. (PHAT) has a DilutionWatch DilutionScore of 46/100, rated MEDIUM dilution risk. Phathom Pharmaceuticals, Inc. has a market capitalization of $764.86M, 79.76M shares outstanding, 179 institutional holders tracked. Key dilution vectors include approximately 10 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
42
💰 Cash Runway
65
📊 Float Risk
25
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
7%
💰 Capital Raise 15%
• Under 12 months cash (10mo)
🔔 Track PHAT — Get forecast alerts →

💹 Market Data

Market Cap$764.86M
Shares Outstanding79.76M
Float60.39M
Cash$180.90M
Debt$163.68M
Short InterestN/A

🏛 Institutional Holdings

179 institutional holders · 75.42M shares
#1 Frazier Life Sciences Management, L.P. 12.47M shares
#2 Medicxi Ventures Management (Jersey) Ltd 7.46M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 5.17M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest11.99M
Days to Cover11.7
% of Float19.9%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Jul 07, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2019
4 INSIDER TRANSACTION Mar 11, 2026
4 INSIDER TRANSACTION Mar 03, 2026
4 INSIDER TRANSACTION Feb 12, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for PHAT Shareholders

Phathom Pharmaceuticals, Inc. (PHAT) has a DilutionScore of 46/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

Cash runway is a key watch item: PHAT has approximately 10 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for PHAT in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for PHAT alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track PHAT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking PHAT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for PHAT
📊 PHAT FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 PHAT Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.